AbbVie Inc. (ABBV) is gaining momentum in the bio-tech market with several
significant events happening around its pipeline and performance. The company’s stock has shown significant promise, with strong returns of 220% over the past five years as well as a 24% rise within a year. AbbVie is also increasing its Oncology pipeline with a new Phase 3 Clinical Trial for
ABBV-383, a Multiple Myeloma investigational asset. It is also involved in agreement license with
FutureGen and
Gilgamesh Pharmaceuticals to develop next-generation therapies for Inflammatory Bowel Disease and Psychiatric Disorders, respectively. The company recently completed the acquisition of
Landos Biopharma and
Cerevel Therapeutics. However, AbbVie's Duopa successor for Parkinson's got denied by the FDA, and company’s Arthritis drug faced a downfall as it went off patent. Despite the challenges, AbbVie has demonstrated resilience by beating Q2 earnings and sales, declaring quarterly dividends, and updating their 2024 EPS view.
Abbvie ABBV News Analytics from Fri, 02 Feb 2024 08:00:00 GMT to Sat, 10 Aug 2024 12:48:29 GMT -
Rating 5
- Innovation 6
- Information 8
- Rumor -6
